Join your colleagues! US Focus On Myeloproliferative Neoplasms and Myelodysplastic Syndromes – August 26-27, 2016 | Westin Alexandria | 400 Courthouse Sq., Alexandria, Virginia 22314
Chair: Srdan Verstovsek, MD, PhD
With few other meetings of this type currently in the United States, this highly-relevant clinical conference will provide the basis to advance understanding, optimal therapy and patient outcomes for MPN and MDS. With its diverse mix of didactic presentations, debates and interactive discussion, you will have the opportunity to update your knowledge in the field, confirm your current practices and receive valuable take-home information on exciting new screening and staging modalities, management approaches and emerging treatment options. Additional information is available at MDSMPNCONGRESS.COM.
Dear Colleagues,
Join me August 26-27, 2016 in Alexandria, VA for the US Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes 2016! This meeting promises to be a first-class educational event that focuses on the latest advances in MPD, MDS and MPN.
This conference will provide a platform to resolve many of the clinical challenges for diagnosis and treatment through presentations and interactive discussions of the latest clinical and research findings pertaining to MPN and MDS. Topics that will be deliberated by recognized experts in the field during this conference include the underlying biology of MPN and MDS and how these events impact clinical practice, including updates in therapeutic interventions of MDS, polycythemia vera, essential thrombocytopenia and myelofibrosis. Gained knowledge from this meeting will provide methods for the advancements of classification and diagnosis of disease, refinement of risk stratification methods and the identification of optimal therapeutic strategies for the enhancement of clinical outcomes and quality of life in patients with MPN and MDS.
As recent discoveries have the potential to change the paradigm of how MPN and MDS are diagnosed and treated, it is imperative that healthcare professionals who care for patients with MPN and MDS are provided an expert review of the most pertinent clinical data pertaining to prognosis, diagnosis, therapy and disease management and guidance for their optimal integration into everyday clinical practice. The US Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes 2016 will bring to the United States the same outstanding, clinically-relevant knowledge pertaining to MPN and MDS that has been provided to the European medical community through its sister conference.
With few other meetings of this type currently in the United States, this highly-relevant clinical conference will provide the basis to advance understanding, optimal therapy and patient outcomes for MPN and MDS. With its diverse mix of didactic presentations, and interactive discussion, you will have the opportunity to update your knowledge in the field, confirm your current practices and receive valuable take-home information on exciting new screening and staging modalities, management approaches and emerging treatment options.
I look forward to seeing you in August, for what is sure to be an educational and informative scientific meeting.
Sincerely,
Srdan Verstovsek, MD, PhD
Conference Chair
